D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 83 Citations 30,476 377 World Ranking 8518 National Ranking 260

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Marco Colleoni mostly deals with Internal medicine, Breast cancer, Oncology, Surgery and Cancer. His research combines Gynecology and Internal medicine. The various areas that Marco Colleoni examines in his Breast cancer study include Clinical endpoint, Disease and Adjuvant therapy.

The concepts of his Oncology study are interwoven with issues in Survival rate, Pathology, Estrogen receptor, Hazard ratio and Survival analysis. His research in Surgery intersects with topics in Standard treatment, Axillary lymph nodes, Metastasis, Sentinel node and Axilla. His Cancer study incorporates themes from Combined Modality Therapy and Biopsy.

His most cited work include:

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
  • Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 (771 citations)
  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (753 citations)

What are the main themes of his work throughout his whole career to date?

Marco Colleoni spends much of his time researching Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Gynecology. His Breast cancer research integrates issues from Clinical trial, Surgery, Disease and Hazard ratio.

His Oncology research is multidisciplinary, incorporating elements of Metastatic breast cancer, Cyclophosphamide, Fluorouracil and Endocrine system. Marco Colleoni has researched Chemotherapy in several fields, including Regimen and Tolerability. His Cancer research incorporates themes from Endocrinology and Pathology.

He most often published in these fields:

  • Internal medicine (80.53%)
  • Breast cancer (70.19%)
  • Oncology (65.62%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (80.53%)
  • Breast cancer (70.19%)
  • Oncology (65.62%)

In recent papers he was focusing on the following fields of study:

Marco Colleoni focuses on Internal medicine, Breast cancer, Oncology, Letrozole and Trastuzumab. His Randomized controlled trial, Cancer, Adverse effect, Palbociclib and Adjuvant investigations are all subjects of Internal medicine research. His Breast cancer research is multidisciplinary, relying on both Clinical trial, Cohort, Placebo, Endocrine system and Adjuvant therapy.

His Oncology research incorporates themes from Chemotherapy, Metastatic breast cancer, Hormone receptor, Clinical endpoint and Hazard ratio. His Letrozole research is multidisciplinary, incorporating perspectives in Neoadjuvant therapy, Estrogen and Urology. His research in Trastuzumab intersects with topics in Biosimilar, Cardiotoxicity and Early breast cancer.

Between 2018 and 2021, his most popular works were:

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (239 citations)
  • Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019 (154 citations)
  • Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. (125 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

His primary areas of study are Breast cancer, Internal medicine, Oncology, Letrozole and Adverse effect. His Breast cancer research includes themes of Radiation therapy, Surgery, Metastasis, Endocrine system and Adjuvant therapy. His Placebo research extends to Internal medicine, which is thematically connected.

The study incorporates disciplines such as Cancer, Trastuzumab, Chemotherapy, Randomized controlled trial and Tamoxifen in addition to Oncology. His research integrates issues of Neoadjuvant therapy, Estrogen receptor, Fulvestrant and Estrogen in his study of Letrozole. His biological study spans a wide range of topics, including Metastatic breast cancer and Palbociclib.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)

2956 Citations

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)

1179 Citations

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

Alan S. Coates;Aparna Keshaviah;Beat Thürlimann;Henning Mouridsen.
Journal of Clinical Oncology (2007)

1055 Citations

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale.
Lancet Oncology (2013)

965 Citations

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates.
Journal of Clinical Oncology (2010)

915 Citations

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)

714 Citations

Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming.
The New England Journal of Medicine (2014)

703 Citations

Adjuvant ovarian suppression in premenopausal breast cancer

Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng.
The New England Journal of Medicine (2015)

643 Citations

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

M. Colleoni;A. Rocca;M. T. Sandri;L. Zorzino.
Annals of Oncology (2002)

526 Citations

Very young women (<35 years) with operable breast cancer: features of disease at presentation

M. Colleoni;N. Rotmensz;C. Robertson;L. Orlando.
Annals of Oncology (2002)

491 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Marco Colleoni

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 123

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 102

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 94

Robert S. Kerbel

Robert S. Kerbel

Sunnybrook Health Science Centre

Publications: 93

Richard D. Gelber

Richard D. Gelber

Harvard University

Publications: 88

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 77

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 74

Jonas Bergh

Jonas Bergh

Karolinska Institute

Publications: 73

Michael Gnant

Michael Gnant

Medical University of Vienna

Publications: 71

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 68

Paolo Veronesi

Paolo Veronesi

European Institute of Oncology

Publications: 66

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 65

Peter A. Fasching

Peter A. Fasching

University of Erlangen-Nuremberg

Publications: 64

Mitch Dowsett

Mitch Dowsett

Breast Cancer Research Foundation

Publications: 63

Monica Morrow

Monica Morrow

Memorial Sloan Kettering Cancer Center

Publications: 62

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 58

Trending Scientists

Anthony J. Weiss

Anthony J. Weiss

Tel Aviv University

Anees Shaikh

Anees Shaikh

Google (United States)

Baochang Shi

Baochang Shi

Huazhong University of Science and Technology

Huayu Tian

Huayu Tian

Chinese Academy of Sciences

Xu Hou

Xu Hou

Zhejiang University

Peter Oelhafen

Peter Oelhafen

University of Basel

Darryn L. Knobel

Darryn L. Knobel

Ross University School of Veterinary Medicine

Shoji Mizushima

Shoji Mizushima

University of Tokyo

Patrick J. Butler

Patrick J. Butler

University of Birmingham

José M. Lorenzo

José M. Lorenzo

Universidade de Vigo

Donatella Zona

Donatella Zona

San Diego State University

Scott K. Baker

Scott K. Baker

Southern Methodist University

Li Ching Lee

Li Ching Lee

Johns Hopkins University

Mary J. O'Sullivan

Mary J. O'Sullivan

University of Miami

Julie Barroso

Julie Barroso

Medical University of South Carolina

Something went wrong. Please try again later.